Results for tag: "Midostaurin"

Midostaurin is an oncology drug used to treat acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM). It is a multi-targeted kinase inhibitor that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Midostaurin is approved by the US Food and Drug Administration (FDA) for the treatment of AML in combination with chemotherapy and for the treatment of SM. Midostaurin is a part of a growing market of oncology drugs, which are used to treat a variety of cancers. These drugs are designed to target specific cancer cells and stop their growth and spread. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. The market for oncology drugs is highly competitive, with many companies developing and marketing new drugs. Some of the major players in the market include Novartis, Pfizer, Merck, AstraZeneca, and Bristol-Myers Squibb. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Show Less Read more